These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 29886514)

  • 1. Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA.
    Khat DZ; Husain M
    Curr Diab Rep; 2018 Jun; 18(7):45. PubMed ID: 29886514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (2014-2022).
    Lin J; Pearson SA; Greenfield JR; Park KH; Havard A; Brieger D; Day RO; Falster MO; de Oliveira Costa J
    Eur J Clin Pharmacol; 2023 Sep; 79(9):1239-1248. PubMed ID: 37449993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints.
    Doumas M; Imprialos Κ; Stavropoulos K; Reklou A; Sachinidis A; Athyros VG
    Curr Pharm Des; 2018; 24(17):1879-1886. PubMed ID: 29865997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life.
    Longato E; Di Camillo B; Sparacino G; Gubian L; Avogaro A; Fadini GP
    BMJ Open Diabetes Res Care; 2020 Jun; 8(1):. PubMed ID: 32591373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in Prescriptions of Cardioprotective Diabetic Agents After Coronary Artery Bypass Grafting Among U.S. Veterans.
    Deo SV; McAllister DA; Al-Kindi S; Elgudin Y; Chu D; Pell J; Sattar N
    Diabetes Care; 2022 Dec; 45(12):3054-3057. PubMed ID: 36256925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Coronary Artery Disease.
    Hofer F; Kazem N; Schweitzer R; Hammer A; Jakse F; Koller L; Hengstenberg C; Sulzgruber P; Niessner A
    Cardiovasc Drugs Ther; 2021 Dec; 35(6):1161-1170. PubMed ID: 33666822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress.
    Luna-Marco C; Iannantuoni F; Hermo-Argibay A; Devos D; Salazar JD; Víctor VM; Rovira-Llopis S
    Free Radic Biol Med; 2024 Mar; 213():19-35. PubMed ID: 38220031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world national trends and socio-economic factors preference of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in China.
    Li C; Guo S; Huo J; Gao Y; Yan Y; Zhao Z
    Front Endocrinol (Lausanne); 2022; 13():987081. PubMed ID: 36277697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-Like Peptide 1 Receptor Agonists Versus Sodium-Glucose Cotransporter 2 Inhibitors for Atherosclerotic Cardiovascular Disease in Patients With Type 2 Diabetes.
    Yanai H; Adachi H; Hakoshima M; Katsuyama H
    Cardiol Res; 2023 Feb; 14(1):12-21. PubMed ID: 36896226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes.
    Wright AK; Carr MJ; Kontopantelis E; Leelarathna L; Thabit H; Emsley R; Buchan I; Mamas MA; van Staa TP; Sattar N; Ashcroft DM; Rutter MK
    Diabetes Care; 2022 Apr; 45(4):909-918. PubMed ID: 35100355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GLP-1 Receptor Agonists and SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: New Insights and Opportunities for Cardiovascular Protection.
    Bertoccini L; Baroni MG
    Adv Exp Med Biol; 2021; 1307():193-212. PubMed ID: 32034729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing cardiovascular benefits between GLP-1 receptor agonists and SGLT2 inhibitors as an add-on to metformin among patients with type 2 diabetes: A retrospective cohort study.
    DeRemer CE; Vouri SM; Guo J; Donahoo WT; Winterstein AG; Shao H
    J Diabetes Complications; 2021 Sep; 35(9):107972. PubMed ID: 34247911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardio-renal outcomes and the direct medical cost of type 2 diabetes patients treated with sodium glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A population-based cohort study.
    Tang EHM; Wong CKH; Lau KTK; Fei Y; Cheung BMY
    Diabetes Res Clin Pract; 2021 Oct; 180():109071. PubMed ID: 34592391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sociodemographic disparities in GLP-1RA and SGLT2i use among US adults with type 2 diabetes: NHANES 2005-March 2020.
    Mittman BG; Le P; Payne JY; Ayers G; Rothberg MB
    Curr Med Res Opin; 2024 Mar; 40(3):377-383. PubMed ID: 38193509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists.
    Scheen AJ
    Diabetes Res Clin Pract; 2018 Sep; 143():88-100. PubMed ID: 29944969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor.
    DeFronzo RA
    Diabetes Obes Metab; 2017 Oct; 19(10):1353-1362. PubMed ID: 28432726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community.
    Nelson AJ; Pagidipati NJ; Aroda VR; Cavender MA; Green JB; Lopes RD; Al-Khalidi H; Gaynor T; Kaltenbach LA; Kirk JK; Lingvay I; Magwire ML; O'Brien EC; Pak J; Pop-Busui R; Richardson CR; Reed M; Senyucel C; Webb L; McGuire DK; Granger CB
    Circulation; 2021 Jul; 144(1):74-84. PubMed ID: 34228476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors.
    Cherney DZI; Udell JA; Drucker DJ
    Med; 2021 Nov; 2(11):1203-1230. PubMed ID: 35590197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Underlying mechanisms and cardioprotective effects of SGLT2i and GLP-1Ra: insights from cardiovascular magnetic resonance.
    Cersosimo A; Salerno N; Sabatino J; Scatteia A; Bisaccia G; De Rosa S; Dellegrottaglie S; Bucciarelli-Ducci C; Torella D; Leo I
    Cardiovasc Diabetol; 2024 Mar; 23(1):94. PubMed ID: 38468245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular and Renal Benefits of Novel Diabetes Drugs by Baseline Cardiovascular Risk: A Systematic Review, Meta-analysis, and Meta-regression.
    Rodriguez-Valadez JM; Tahsin M; Fleischmann KE; Masharani U; Yeboah J; Park M; Li L; Weber E; Li Y; Berkalieva A; Max W; Hunink MGM; Ferket BS
    Diabetes Care; 2023 Jun; 46(6):1300-1310. PubMed ID: 37220263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.